ArticleDiabetes care2008
Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range.
Article in Diabetes care, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02613897 (A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy
Who cites it
22 citing papers in PubMed.
- Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.Diabetes care · 2020Trial
- Trial
- Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study.The Journal of physiology · 2017Trial
- Strong association between insulin-mediated glucose uptake and the 2-hour, not the fasting plasma glucose concentration, in the normal glucose tolerance range.The Journal of clinical endocrinology and metabolism · 2014Trial
- Insulin Sensitivity and Insulin Secretion in Adults With Friedreich's Ataxia: The Role of Skeletal Muscle.The Journal of clinical endocrinology and metabolism · 2025Observational
- Impaired plasma glucose clearance is a key determinant of fasting hyperglycemia in people with obesity.Obesity (Silver Spring, Md.) · 2024Article
- The promise(s) of mesenchymal stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model systems.Scientific reports · 2021Article
- Glucose-Mediated Glucose Disposal at Baseline Insulin Is Impaired in IFG.The Journal of clinical endocrinology and metabolism · 2019Article
- The Vasculature in Prediabetes.Circulation research · 2018Review
- Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose.Diabetes · 2017 · on this mapArticle
- Decreased basal hepatic glucose uptake in impaired fasting glucose.Diabetologia · 2017Article
- Normal fasting plasma glucose predicts type 2 diabetes and cardiovascular disease in elderly population in Taiwan.QJM : monthly journal of the Association of Physicians · 2016Article
- Exercise resistance across the prediabetes phenotypes: Impact on insulin sensitivity and substrate metabolism.Reviews in endocrine & metabolic disorders · 2016Review
- Treatment of prediabetes.World journal of diabetes · 2015Review
- Altered amyloid precursor protein processing regulates glucose uptake and oxidation in cultured rodent myotubes.Diabetologia · 2014Article
- Prediabetes: a prevalent and treatable, but often unrecognized, clinical condition.Journal of the Academy of Nutrition and Dietetics · 2013Article
- A higher-carbohydrate, lower-fat diet reduces fasting glucose concentration and improves β-cell function in individuals with impaired fasting glucose.Metabolism: clinical and experimental · 2012Article
- Predicted 25-hydroxyvitamin D score and change in fasting plasma glucose in the Framingham offspring study.European journal of clinical nutrition · 2012Article
- Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan Diabetes Prevention Study.The review of diabetic studies : RDS · 2011Article
- Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose.Diabetes care · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the contribution of decreased glucose clearance to the rise in fasting plasma glucose (FPG) in the nondiabetic range. RESEARCH DESIGN AND
methodsA total of 120 subjects with normal glucose tolerance received an oral glucose tolerance test and euglycemic insulin clamp with 3-[(3)H]glucose. The basal and insulin-stimulated rates of glucose appearance, glucose disappearance, and glucose clearance and the basal hepatic insulin resistance index were calculated. Simple Pearson's correlation was used to assess the relationship between variables.
resultsThe increase in FPG (range 75-125 mg/dl) correlated (r = 0.32, P < 0.0001) with the increase in BMI (20-50 kg/m(2)). The fasting plasma insulin (FPI) concentration also increased progressively with the increase in BMI (r = 0.62, P < 0.0001). However, despite increasing FPI, the basal glucose clearance rate declined and correlated with the increase in BMI (r = -0.56, P < 0.0001). Basal hepatic glucose production (HGP) decreased with increasing BMI (r = -0.51, P < 0.0001) and correlated inversely with the increase in FPI (r = -0.32, P < 0.0001). The hepatic insulin resistance (basal HGP x FPI) increased with rising BMI (r = 0.52, P < 0.0001). During the insulin clamp, glucose disposal declined with increasing BMI (r = -0.64, P < 0.0001) and correlated with the basal glucose clearance (r = 0.39, P < 0.0001).
conclusionsThese results demonstrate that in nondiabetic subjects, rising FPG is associated with a decrease (not an increase) in basal hepatic glucose production and is explained by a reduction in glucose clearance.
Indexed as
Identifiers
18000182What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.